REGULATORY

JPMA Will Work to Secure Quality, Transparency of Clinical Research for Purpose of Advertising: Vice President

December 15, 2014

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japan Pharmaceutical Manufacturers Association (JPMA) will discuss with the health ministry ways to secure the quality and transparency of clinical research conducted for the purpose of advertising, JPMA Vice President Isao Teshirogi said on December 12. Dr Teshirogi made…

To read the full story

Panel Reveals Final Report Calling for Legal Regulations for Clinical Research
December 12, 2014

REGULATORY

Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
March 5, 2026
MHLW to Launch Priority Review Pathway for Overseas Alternatives amid Drug Shortages
March 5, 2026
LDP Health Panel Approves Health Insurance Bill with OTC-Like Drug Charges
March 5, 2026
Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…